Friday, November 21, 2008

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder

THOUSAND OAKS, Calif. – Nov. 21 – Amgen (Nasdaq: AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate(TM) (romiplostim) in the European Union (EU). The CHMP recommends Nplate for adult chronic immune (idiopathic) thrombocytopenia purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised patients where surgery is contra-indicated.

Read the rest of this entry

Posted in Press Releases, Product News

Wednesday, November 19, 2008

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

THOUSAND OAKS, Calif., Nov. 19  – Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study’s independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Monday, November 10, 2008

Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe

Hands-On Science Research Program Expansion Brings the Amgen Foundation’s Total Commitment to Amgen Scholars to $27.5 Million

Applications for 2009 Amgen Scholars U.S. Program Now Available

THOUSAND OAKS, Calif. – Nov. 10, 2008 – Each year, hundreds of students from across the United States (U.S.) participate in the Amgen Scholars Program under renowned faculty members at the country’s leading universities. Now, the same opportunity will be extended to undergraduates throughout Europe. As part of its mission to advance science education, the Amgen Foundation, in partnership with three of Europe’s leading universities, today announced the launch of the Amgen Scholars Program in Europe.

Read the rest of this entry

Posted in Philanthropy

Friday, November 07, 2008

Amgen Positioned to Deliver Attractive Growth Over Next Five Years

NEW YORK – Nov 07, 2008 – At an Amgen (Nasdaq: AMGN) meeting of about 200 securities analysts and investors in New York City today, several members of its senior management team outlined the Company’s growth strategy, which includes delivering on its pipeline—including the experimental bone drug denosumab—growing in-line products and continuing to pursue operating efficiencies.

"In 2001, Amgen had two blockbuster products and today we have five blockbusters on the market," said Amgen Chairman and CEO Kevin Sharer. "Over the next five years we could have three more drugs achieve blockbuster status: Sensipar(R) (cinacalcet), denosumab for osteoporosis and denosumab for cancer-related indications."

Read the rest of this entry

Posted in Press Releases

Monday, November 03, 2008

Call for Applications: The Amgen Award for Science Teaching Excellence

34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates

THOUSAND OAKS, Calif. – Nov. 3 – Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 18th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates.

Read the rest of this entry

Posted in Philanthropy, Press Releases